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ABSTRACT 
 
 
 
 Tau is a protein normally associated with the assembly of microtubules, but it 
tends to hyperphosphorylate leading to its aggregation which is a major cause of several 
neurodegenerative disorders, termed tauopathies that includes Alzheimer’s 
disease. Alternative splicing of exon 10 in the tau gene has also been suggested to play an 
important role in the pathogenesis of tauopathies.  When tau exon 10 is included in the 
tau protein, neurofibrillary tangles (tau aggregates) are more prevalent.  To search for 
potential treatments for tauopathies, our laboratory previously developed a luciferase 
reporter assay to screen compounds that decrease tau exon 10 inclusion and identified 
five molecules from 1,040 FDA approved drugs for initial luciferase activity.  The goal of 
our project was to further characterize the key five compounds identified in the original 
screen using the luciferase assay and RT-PCR.  We demonstrated that all five compounds 
tested produced statistically significant increases in luciferase activity relative to DMSO 
control at 5 µM concentrations, validating the original screening.   
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BACKGROUND 
 
Alzheimer’s Disease  
 Alzheimer’s disease (AD) is a progressive neurodegenerative disorder which 
predominantly affects the elderly.   AD involves the destruction of neurons which control 
memory, thought and language.  Currently in the United States, there are over five 
million people living with the disease.  There are two types of AD: Early-onset, and late-
onset.  Late-onset cases of AD are primarily seen in the 65 years and over category.  
Early-onset AD, sometimes associated with genetic predisposition, is seen in patients 
under the age of 65.   
 There are seven stages of AD, increasing from no impairment to very severe 
decline.  A patient who is diagnosed with AD could fall within any of these seven stages 
at any given time.  The disease also advances at different rates in different patients.  
Some people end up only living a few years with AD, whereas others can live with the 
disease for as long as twenty years (Alzheimer’s Association, 2007).   
 
Symptoms 
 Several symptoms can be observed in an AD patient.  Some of the most prevalent 
symptoms are memory loss, disorientation to time and place, changes in mood and 
behavior, problems with language, and finally changes in personality.  Some of these 
symptoms are synonymous with the normal aging process such as memory loss, but AD 
patients experience these symptoms more frequently.   
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Alzheimer’s Disease Risk Factors 
 Certain risk factors have been observed in AD patients.  The most obvious factor 
at the present time is age.  As the brain continues to function, some of the proteins build 
up and cause neuronal cell death which results in the loss of brain function.  Another risk 
factor is family history; however, in only five percent of cases is true familial AD 
observed.  Certain abnormal genes, if inherited, will definitely cause the disease.  For 
example, certain mutations found in PS1, PS2 or APP genes can cause AD.   It is 
significant that mutations in each of these three genes have one thing in common, they 
each increase the formation of highly neurotoxic Aβ peptide from amyloid precursor 
protein (APP).  The “amyloid cascade hypothesis” proposes a key role for neurotoxic Aβ 
in the formation of senile plaques and AD, but this mechanism is not the topic of this 
MQP, so will not be discussed in detail here.  
 In addition to genes that cause AD, some genes just increase the risk of 
developing AD.  One such gene is the apoliprotein E-e4 (APOE-e4) gene.  There are 
three common forms of the APOE gene, and the e4 form increases the risk of developing 
AD.  Normally this gene is responsible for the creation of a protein that carries 
cholesterol in the blood stream, but when a person inherits either one or two copies of 
APOE-e4 they are more likely to develop AD.  The APOE-e4 gene also accelerates the 
formation of highly neurotoxic amyloid-beta protein from amyloid precurson protein.   
 The final two risk factors that are avoidable are head trauma and unhealthy hearts.  
It has been proven that a healthy heart can keep the brain healthy for currently unknown 
reasons; however one hypothesis is that a healthy heart increases blood flow to the brain 
(Alzheimer’s Association, 2007). 
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Current Treatments 
 Since AD is such a prevalent disease, the United States government has poured 
money into research that could help treat the disease.  Right now the current treatments 
only slow down the progression of the disease, they don’t stop it (Alzheimer’s 
Association, 2007).  And they treat only symptoms, not the underlying neurodegenerative 
cause.  Five drugs are currently FDA approved for treating AD (dates of FDA approval 
and alternative names in parentheses):  Tacrine (1993 Cognex®), Donepezil 
hydrochloride (1996, Aricept®), Rivastigmine (2000, Exelon®), Galantamine 
hydrobromide (2001, RazadyneTM,  formerly called Reminyl®), Memantine HCI (2003, 
NamendaTM).  Each of these drugs blocks acetylcholine esterase, the enzyme that 
degrades acetylcholine, thereby increasing acetylcholine neurotransmitter in syapses.  
Vitamin E treatment also may slow down the disease, but can not completely stop the 
progression, or repair the damage that has already been done (Alzheimer’s Association, 
2007). 
 
Alzheimer’s Disease Sociology 
 Since the treatments can’t stop the disease, patients are forced into nursing homes 
or forced to hire help faster than those people without the disease, and as such it is 
costing these people thousands of more dollars per year (Figure-1) (Alzheimer’s 
Association, 2007).   
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Figure 1:  The High Cost of Alzheimer’s 
Disease.  Comparison of average medicare 
costs for hospital, nursing home, and home 
health care for beneficiaries 65+ with 
Alzheimer’s Disease and other dementias 
(light gray histobars) as compared with 
other beneficiaries (dark histobars) 
(Alzheimer’s Association, 2007). 
 
 
 
 
Diagnosis 
Perhaps one of the biggest problems with AD is there is no definitive test that 
determines whether a patient has the disease.  In order to diagnose the disease, doctors 
perform multiple memory tests, such as the mini-mental state examination (MMSE).  
They also use blood tests to determine if there are any infections or other conditions that 
could be causing the memory problems.  Finally, doctors can use brain imaging 
techniques such as an MRI or PET scan to try and see structural and functional changes 
that might have occurred.  Figure-2 shows a PET scan of a normal brain (left panel) 
compared to an Alzheimer’s patient’s brain (right panel) (Alzheimer’s Association, 2007) 
illustrating the lowered brain activity associated with AD. 
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 Figure 2:  PET Scan Comparison of Normal and Alzheimer’s Brains.  On the left is a PET 
scan of a normal brain.  Note that there is lots of red color (usually denoting labeled glucose uptake) that 
indicates healthy brain function.  On the right is a PET scan of an Alzheimer’s disease patient.  Note the 
lack of red color indicating less brain activity (National Institute on Aging, 2006). 
 
 
 
 AD is difficult to positively diagnose prior to death.  Recently some scientists 
have claimed to develop magnetic resonance imaging (MRI) assays that detect senile 
plaques in patients brains.  And other scientists claim that the quantization of Aβ released 
into the cerebrospinal fluid (CSF) is an accurate measure of AD in progress.  But in the 
end, the only way that AD can be truly diagnosed is after death during an autopsy.  When 
medical examiners analyze slices of the brain, they will see the tell tale amyloid plaques 
caused by the build up of amyloid-β and the neurofibrillary tangles which are caused by 
the build up of tau protein in the brain.   
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Alzheimer’s Disease Mechanism 
 The cellular causes of neurodegeneration in AD are currently unknown, however 
much research has focused on two hallmark features of the disease, extracellular senile 
plaques (composed of amyloid) and intracellular neurofibillary tangles (composed of 
Tau) (Goedert et al., 2006).  Figure 3 shows a summary diagram of some of the key 
events that are currently thought to participate in neuronal apoptosis, including the 
production of neurotoxic Aβ peptide (yellow box in the diagram) and Tau 
hyperphosphorylation (diagram lower center).  For years scientists have argued over 
whether Tau or Amyloid are the direct causes of AD, and whether one or both are disease 
side effects, but most current models of the disease argue both Aβ buildup and tau 
hyperphosphorylation are strong cellular causes. Because this MQP focused on Tau, the 
remainder of the discussion will focus on Tau not Amyloid.    
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Figure 3.  Diagram of Alzheimer’s Disease Mechanism.  Note the central role proposed for both Aβ 
peptide (yellow box) and Tau hyperphosphorylation (lower center).  (Calbiochem, 2000).   
 
Tau Protein 
Tau protein is a highly soluble microtubule-associated protein (MAP) that binds 
to tubulin to stabilize microtubules and promote tubulin assembly into microtubules.  Tau 
protein is a short rod-like molecule that forms cross bridges between microtubules in 
vitro.  For the most part, the tau protein is responsible for the polymerization of tubulin 
which leads to better stability and assembly in neuronal process extension (Weingarten et 
al., 1975).   
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Tau Phosphorylation 
There are two ways that tau is able to control microtubule assembly:  
phosphorylation and isoforms (Drubin et al., 1986).  The phosphorylation of tau is 
regulated and performed by several kinases.  Phosphorylation by these kinases is 
essential for the posttranslational modifications of the tau protein.  There are two specific 
types of kinases that regulate tau:  proline and non-proline directed protein kinases.  The 
proline directed protein kinases (PDPK) phosphorylate tau through modified serine-
proline or threonine-proline tau motifs.  The three main PDPKs are tau kinase I, cdk5, 
and stress kinases.  The non-proline directed protein kinases (NPDPK) phosphorylate tau 
through serine or threonine residues that are not followed by proline.  The main NPDPKs 
are cyclic-AMP dependent kinase, Ca2+/calmodulin dependent kinase, protein kinase C, 
and microtubule affinity regulating kinase.   
 
 
Tau Domains 
Ultimately, phosphorylation of tau allows for different binding sites (Figure-4, 
domains m1, m2, m3, m4) where the microtubule can be bound and moved to create a 
more stable structure, and the same holds true for the tau isoforms (Gómez-Ramos et al., 
2004). 
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Figure 4: Tau Protein Domains.  The diagram illustrates where phosphates are added (red), where the 
serine/threonine proline kinases can bind (green), where the microtubule binding domains are (m1, m2, m3, 
m4), and where each of the alternatively spliced exons (exons 2, 3 and 10) are (orange E boxes) (Kuret, 
2006). 
 
One of the major structural characteristics of the tau protein is the presence of a 
four carboxyl-terminal tandem repeat sequences of 31 or 32 amino acids that are encoded 
by exon 9, 10, 11, and 12.  The four carboxyl-terminal tandem repeat sequence is used to 
bind and stabilize microtubules.   As seen in figure 3, there is a proline rich region in the 
middle of the protein.  Without this proline rich region, the tau protein will not bind to 
microtubules.  The microtubule binding region that is seen in figure 3 contains a repeated 
domain, and without that repeated domain, tau will not bind to microtubules either.  
There is also a neutral domain in the N-terminal region, and a region in the first half of 
the C-terminal tail of the protein that when disrupted cause the protein to become less 
efficient at microtubule bundling.   
Tau mRNA is expressed mainly in neurons and in some oligodendrocytes.  
Within nerve cells, the axon holds most of the tau protein.  Tau does not seem to be an 
essential protein in mice because when its gene is inactivated, there are no adverse affects 
on that phenotype.  Only the amount of microtubules in some small-caliber axons is 
reduced (Spillantini et al., 1998).  
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Tau Isoforms 
The human tau gene contains sixteen exons, and encodes a full-length 441 amino-
acid protein.  The human gene is also more than 100 kilobases long and has been mapped 
to chromosome 17q21.  The first exon is the promoter, and exons 4A, 6 and 8 are not 
present in human mRNA.  Exons 2, 3 and 10 are alternatively spliced which create six 
different mRNAs that have been observed.   These six mRNAs are responsible for the six 
different isoforms of the tau protein.  Exons 2 and 3 can be found in the N-terminal 
region of the protein, and exon 10 can be found in the C-terminal end of the protein.  The 
adult tau proteins can range anywhere from 352 to 441 amino-acids long.  The tau protein 
isoforms that have been found in fetuses exclude exons 2, 3 and 10.   From species to 
species, there are great differences in the tau protein formation.  For instance, in rats there 
are only three isoforms (Yu et al., 2004).  These regions as well as all six isoforms of the 
protein can be seen in Figure 5 (Kanai et al., 1992). 
  
 
 
 
 
 
Figure 5:  Tau Isoforms.  This 
figure shows all six isoforms of 
the tau protein including the 
composition of the N-terminal 
region and C-terminal tail for all 
forms (Kanai et al., 1992). 
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Tau in Alzheimer’s Disease 
Neurodegenerative disorders commonly known as tauopathies are caused by the 
irregular expression or malfunction of tau protein, the protein normally recognized to 
bind and assemble microtubules.  AD is one of the more common tauopathies.  Many 
neurodegenerative disorders such as frontotemporal dementia and parkinsonism are 
linked to chromosome 17 (FTDP-17).  AD is linked to chromosomes 21 (amyloid 
precursor protein), 14 (aopE), and 17 (tau).  All these disorders possess the familiar 
pathological characteristic of the development of insoluble intraneuronal aggregates 
compiled of hyperphosphorylated tau proteins that develop neurofibrillary tangles.  
Neurofibrillary degeneration, also known molecularly as tauopathies, affects the cortical 
and subcortical regions of the brain.  Neurofibrillary degeneration is characterized by the 
presence of intraneuronal inclusions that are found in the brain.  These inclusions react 
with anti-tau antibodies and form bundles that are called neurofibrillary tangles.  The 
theory that tau genotype could affect the progress of neurodegenerative diseases came 
from the detection of a polymorphic marker of the tau gene that is over expressed in 
progressive supranuclear palsy.   The tau protein and tauopathies are genetically related 
since linkage analysis of frontotemporal dementia and parkinsonism and many other 
neurodegenerative diseases were mapped to the same region as the tau gene on 
Chromosome 17 (Schraen-Maschke et al, 2004).  
 Many mutations were discovered in the tau gene from patients with such 
neurodegenerative diseases.  A minimum of 29 discrete pathogenic mutations of the tau 
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gene were recognized in many families with frontotemporal dementia (FTDP-17).  A 
majority of these frontotemporal dementia Tau mutations were found to be in the coding 
region or close in proximity to the splicing donor site of intron 10.  Exonic mutations, 
found in close proximity to the microtubule-binding domain, alter the ability of tau to 
encourage proper microtubule assembly.  Intronic, silent, and several missense mutations 
have been demonstrated to influence mRNA splicing of exon 10 (Umeda et al, 2004).  
Furthermore, it has been demonstrated that a single group of mutations in coding 
sequences is able to modify the capacity of tau to interact with microtubules.  Other 
missense mutations found in the coding region do not alter the affinity of tau protein to 
microtubules.  These mutations, as well as mutations in introns, affect the splicing of 
exon 10.  Two major Tau isoforms, 4R Tau (4 repeats) and 3R Tau (3 repeats) are created 
as a result of alternative splicing of tau exon 10.  The 3R/4R Tau ratio, normally 1:1, is 
altered with a shift towards a higher production of the 4R protein.  Further investigation 
of tau mRNA and proteins demonstrated that tau protein with exon 10 inclusion is in 
excess in patients with frontotemporal dementia and progressive supranuclear palsy 
which shows that abnormal splicing of exon 10 exists in other neurodegenerative diseases 
besides frontotemporal dementia (Yu et al, 2004).   No tau mutations have yet been 
mapped to AD. 
 The role of the tau gene in the pathogenesis of tauopathies such as FTDP-17 and 
progressive supranuclear palsy was not understood until mutations of the gene were 
discovered.  The fact that a cluster of mutations affects the splicing of exon 10 introduces 
the hypothesis that polymorphisms within introns 9 or 10 that influence tau splicing 
could cause tauopathies.  It is known that the splicing of exon 10 is developmentally 
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controlled.  In fact, infants only express exon 10 excluded mRNA.  Exon 10 inclusion 
augments with age, with the normal ratio of exclusion to inclusion of exon 10 being 1:1.  
Many neurodegenerative diseases are dependent upon age.  Therefore it is feasible that 
variations in the splicing of exon 10 have lasting effects on the aggregation of tau 
proteins.  As a result, the detection of drugs or naturally occuring molecules that alter tau 
splicing could be beneficial for treatment of FTDP-17, PSP, and other neurodegenerative 
diseases (Yu et al, 2004). 
 Consequently, attempts at discovering compounds that hinder the construction of 
Tau filaments and the hyperphosphorylation of tau proteins have been made.  The 
discovery of mutations that support the inclusion into tau mRNA of exon 10 in several 
FTDP-17 patients offers support that exon 10 inclusion may have a role in other 
tauopathies. 
 
Design of Assays to Detect Alternative Splicing in SMN and Tau 
 Dr. Jianhua Zhou’s lab (UMass Medical School, Worcester) has established a 
cell-based screen for small compounds that possess the ability to encourage the inclusion 
of exon 7 in the survival motor neuron (SMN) gene, responsible for Spinal Muscular 
Atrophy (SMA).  This system was organized so that compounds that increase luciferase 
activity would be the ones that heightened the inclusion of exon 7 into SMN mRNA.  The 
system was constructed using a mini-gene with a minimal length exon 7 with a luciferase 
reporter fused to exon 8.  Therefore, when exon 7 was introduced into the mRNA, 
luciferase would be within a reading frame, whereas in the absence of exon 7 the mRNA 
would lack the luciferase activity (Zhang et al, 2001).   
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 Dr. Zhou’s lab has also used similar technology to construct an assay to detect tau 
exon 10 exclusion.  This system was assembled after identifying the fact that a minimal 
distance of intron 10 is necessary for the proper splicing of exon 10 as well as the fact 
that protein SRp20 lowered the integration of exon 10 into wild-type and mutant tau pre-
mRNAs (Yu et al, 2004).  It was determined that a minimum of 1,294 base pairs of intron 
10 is required for proper splicing of exon 10.  The system was designed to identify 
compounds that can reverse tau alternative splicing (i.e. inclusion of exon 10) through 
biological molecules such as SRp20 protein.  The system is shown in Figure 6. 
 
 
 
 
 
 
 
 
Figure 6:  Design of the Cell-Based Luciferase System Used by Dr. Zhou’s Lab to Evaluate Tau Exon 
10 Splicing.   Panel A shows a luciferase mini-gene construct with firefly luciferase (right side) fused 
downstream of Tau exon 11.  The point mutation M14 (G to T) in intron 10 increases the inclusion of exon 
10.  Exon 10 inclusion into this construct would introduce a stop codon (TAG) by changing A to T, causing 
luciferase to not be expressed.   Panel B shows the control mini-gene construct similar to Panel A but 
without the mutation in intron 10, so exon 10 inclusion will be minimal.  Panels C &D show the structure 
of the constructs with and without exon 10, respectively (Yu et al., 2004). 
 
 The first plasmid construct in the screening system (Figure 6A) included a firefly 
luciferase reporter fused downstream of tau exon 11.  Two mutations were made in the 
tau gene.  The first base change was in exon 10, and generates a stop codon that does not 
alter exon 10 splicing patterns, while the second base change is a point mutation in intron 
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10 (labeled M14 in the figure) that produces an increase in exon 10 inclusion, to create a 
plasmid construct which would help recognize the molecules that encourage exclusion of 
exon 10.  Without the point mutation it would be difficult to identify compounds using 
the wild-type form of the gene since most wild-type mRNAs from tau exclude exon 10.  
With this arrangement of the construct, when exon 10 is included (previously correlated 
with increased chance of a disease state), translation discontinues at the stop codon of 
exon 10, prohibiting the production of luciferase.  When exon 10 is excluded from the 
mRNA (via an active therapeutic), translation continues through exon 11 reaching the 
luciferase gene.  Therefore desirable drugs that induce an increase in the exclusion of 
exon 10 will generate an increased luciferase signal (Yu et al., 2004). 
 The second plasmid in the screening system (Figure 6B) is a control construct that 
used a comparable plasmid mini-gene to the one previously described, with the exception 
that the control construct does not contain the stop-codon, and the firefly luciferase is 
substituted with Renilla luciferase, which is minimally affected by the 
exclusion/inclusion of exon 10.  This control mini-gene construct was cloned in a 
hygromycin expression vector.    
 Using the two constructs, stable cell lines containing the plasmids were made in 
neuroblastoma SKN-MC cells using neomycin and hygromycin as selectable markers.  
These stable transfected cell lines were used to demonstrate the minimum length of tau 
exon 10 required for correct splicing (Yu et al., 2004), and were also used by the Zhou 
lab in unpublished findings to screen 1,040 FDA approved drugs by luciferase levels and 
tau RT-PCR for exon 10 exclusion. 
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PROJECT PURPOSE 
 
 
 
 As stated in the Background, specific tauopathies have previously been associated 
with the inclusion of exon 10 in tau splicing.  The purpose of this project was to use the 
plasmid based system of Yu et al, 2004, to further analyze five initial drugs that appeared 
to increase exon 10 exclusion in their original screen of 1,040 FDA approved compounds 
(unpublished data).  Initially, the luciferase activity induced by certain compounds will be 
measured, then the potential positives will be validated by RT-PCR of tau mRNA.  The 
identification of pharmaceuticals that modulate tau splicing can be prospective treatments 
for patients with tauopathies (Yu et al, 2004).  
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METHODOLOGY 
 
Cell Culture 
 Standard sterile technique was used to grow SKN-MC cells containing the 
luciferase plasmid system described in Yu et al., 2004, for screening tau exon-10 
exclusion.   Persistent cell death proved to be a problem that occupied an extensive 
portion of the time spent in the lab.  Therefore, the experimentation of different 
compositions of media was required to allow for cell viability.  At first it was thought to 
be a contamination problem, but the cells continued to die after the incubator was 
decontaminated.  First the percentage of penicillin/streptomycin antibiotic mixture was 
increased from 1% to 2%.  Although some of the cells began to proliferate, they were not 
growing fast enough.  Subsequently, the amount of fetal bovine serum was increased 
from 10% to 12.5%.  The cells began to proliferate at a satisfactory rate necessary for 
experimentation. 
 The cells were finally maintained in a 10-cm Petri dish in Dulbecco’s modified 
Eagle’s medium supplemented with 12.5% fetal bovine serum and a 2% 
penicillin/streptomycin antibiotic mixture.  These cells were allowed to grow to 
confluency and then were split to a new 10-cm Petri dish with a cell concentration of 
1x106 cells per mL. 
  
Luciferase Assay 
 The cells were washed twice with PBS,  then removed from the 10-cm Petri 
dishes using Trypsin.  Using sterile technique, 2x104 cells per 200 µL of medium were 
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added to 45 wells of a 96-well plate.  The plates were covered and placed in a 37°C, 5% 
CO2 humidified chamber overnight to allow for cell adhesion.  Five FDA approved drugs 
(Microsource Discovery System, Inc.) previously identified by Zhou’s lab as decreasing 
exon-10 inclusion (Colchicine, Podophyllotoxin, Gentian Violet, Peruvoside, and 
Sanguinarine Nitrate) were dissolved in DMSO to achieve a concentration of 1 M.  These 
FDA approved drugs were added to the cells in 1, 5, and 10 µM concentrations.  A 1% 
DMSO control was also used.   
 The cells were then allowed to incubate at 37°C for 24 and 48 hours.  After these 
time periods, the cells were washed with PBS, which was then removed.  A commercial 
source luciferase lysis buffer was then added to the cells.  The plates were then incubated 
to allow for cell lysis.  The 96-well plate was then placed in a Perkin Elmer EnVision 
2102 multilabel reader, and light emission monitored at 700 nm.  This experiment was 
repeated twice.   
 
RNA Extraction 
 The cells were washed twice with PBS, and removed from the 10-cm Petri dishes 
using Trypsin.  Using sterile techniques, 1x106 cells were added per 1mL medium to each 
of the 6 wells.  The cells were allowed to adhere and grow overnight in a 37°C, 5% CO2 
humidified chamber. 
 Cells were again washed twice with PBS, then lysed directly in the culture by 
adding 0.5mL Trizol (Invitrogen, Carlsbad, CA, USA).  The cell lysate was passed 
several times through a pipette, to thoroughly lyse the cells and extract the RNA into the 
aqueous phase.  The samples were incubated for 5 minutes at 15-30°C to allow complete 
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dissociation of nucleoprotein complexes.  The contents of each well were transferred to a 
separate 1.5mL eppendorf tube.  Next, 100 µL of chloroform was added to each tube, and 
the tubes were shaken vigorously by hand for 15 seconds.  The samples were then 
incubated at 15-30°C for 2-3 minutes.  The samples were then centrifuged at 12,000 x g 
for 15 minutes at 2-8°C to separate the aqueous and organic liquid phases.  The upper 
aqueous phase was then removed to a fresh tube and mixed with 0.25 mL isopropyl 
alcohol.  The samples were then allowed to stand at 15-30°C for 10 minutes followed by 
centrifugation at 12,000 x g for 10 minutes (2-8°C) to pellet the total cellular RNA.  The 
supernatant was discarded and the RNA pellet was washed with 0.5 mL of 75% ethanol.  
Each sample was mixed by vortexing, then centrifuged at 1500 x g for 5 minutes (2-8°C).  
The RNA pellet was allowed to air dry for approximately 5-10 minutes, and if not 
completely dry was dissolved in RNase-free water.  The samples were analyzed by a 
spectrophotometer at optical densities of 260nm and 280nm.  The ratio of 
OD260nm/OD280nm had to be greater than 1.6 for the RNA to be pure enough to 
proceed.  The samples were then stored at -80˚C until reverse transcription. 
 This experiment proved to be difficult due to the continued cell death.  Therefore, 
the quality of RNA was diminished to the point where it was unusable.  Four attempts 
were needed to achieve the proper optical density ratio necessary to proceed with reverse 
transcription.  
 
Reverse Transcription 
 One microgram of extracted RNA from each well was added to 1µL of oligo(dT) 
primers, with a forward sequence of 5’GCGAATTCGGTGAACCTCCAAAATCAGG-
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GGATCG-3’ and a reverse Luciferase 200 primer with the sequence 5’-ATAGTCTCT-
GCCAACCGAAC-3.’  RNase-free water was added until a final volume of 5 µL was 
achieved.  The tubes were then placed in thermocycler at 70°C for 5 minutes to denature 
the RNA, followed by incubation at 4°C for 5 minutes, and spin cycle for 10 seconds (to 
pellet the solution in the tube).  Each 5 µL mixture was added to 4.5 µL RNase-free 
water, 4 µL buffer, 4 µL MgCl2, 1µL dNTP, 0.5 µL RNase inhibitor, as well as 1µL 
reverse transcriptase (Promega).  Each tube was placed in the thermocylcer for 1 cycle 
consisting of 5 minutes at 25°C, 1 hour at 42°C, and 15 minutes at 70°C (an increasing 
temperature series of reverse transcription).  The cDNA samples were then stored at -
20°C until PCR. 
 
PCR 
 For the polymerase chain reaction, 12.5 µL of Choice Blue Master Mix(Denville 
Scientific Inc.) containing dNTPs and taq polymerase were added to 0.5 µL of template, 
10 µL of water, 1 µL of forward primer, and 1 µL of reverse primer. The sample was then 
heated at 94°C for 5 minutes.  Next, 30 cycles of the following temperatures and times 
were conducted:  94°C for 45 seconds, 50°C for 45 seconds, and 72°C for 1 minute 30 
seconds.  Next, a 10 minute 72°C polishing step followed.  Following this reaction, 10 µL 
of the reaction mixture were electrophoresed on a 1.5% agarose gel for 60 minutes. 
 25 
RESULTS 
 
 The main objective of this project was to confirm the previous unpublished 
identification by Zhou’s lab, of five FDA approved pharmaceuticals that minimize the 
inclusion of tau exon 10.  This was accomplished by using a cell based luciferase assay 
system developed by Yu et al., 2004, and was confirmed by the use of tau RT-PCR.   
 
Luciferase Assay 
 Initially, conditions had to be developed for growing the transfected cells.  
Persistent cell death proved to be a problem that occupied an extensive portion of the 
time spent in the lab.  This was thought to be a contamination problem, but the cells 
continued to die after the incubator was decontaminated, so the percentage of 
penicillin/streptomycin antibiotic mixture was increased from 1% to 2%.  This did not 
solve the problem, so the fetal bovine serum was increased from 10% to 12.5%, which 
finally allowed the cells to grow at a satisfactory rate necessary for experimentation. 
 Of the five compounds tested: Colchicine (11-8C), Podophyllotoxin (2-7H), 
Gentian Violet (3-7A), Peruvoside (7-4H), and Sanguinarine Nitrate (5-9E), all 
compounds proved to statistically increase luciferase activity.  A sample of the results of 
the luciferase assay is shown in Table I, and these results are represented in a histoplot in 
Figure 7. 
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Table 1:  Sample Luciferase Assay Data for Five Compounds Tested for 24 Hrs 
10 µM 5 µM 1 µM Compound 
4532 5336 5444 7780 5584 6040 1936 1160 1160 3-7A 
1872 776 1180 4000 4520 4696 1160 1212 1196 5-9E 
2340 2708 2816 3252 2956 2832 1644 2144 2468 11-8C 
5236 5076 5200 3984 3816 3516 2472 2600 2984 7-4H 
2132 2612 3436 2184 2800 2508 2676 2288 1400 2-7H 
1240 1496 1836 1476 1588 1612 984 1196 1068 Control 
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Figure-7:  Histoplots of Luciferase Activity Versus Drug Concentration for the Five Compounds 
Tested.  Upper panel denotes 1 uM compound concentrations; middle panel, 5 uM; and lower panel 10 uM.  
Each histobar denotes the means of 3 independent trials.  Error bars denote one standard deviation.  P 
values were calculated using a pairwise t-test.  
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As seen in Figure-7, at 1 µM concentration (upper panel) all compounds tested showed 
average luciferase activities above the DMSO control, however only 7-4H and 11-8C 
showed statistically signficant elevations (p < 0.05) using a pairwise t-test.   Compound 
7-4H was the most active at this concentration.  At 5 µM concentration (middle panel) all 
five drugs showed statistically significant increases (p < 0.05) above the DMSO control.  
At this concentration, all compounds except 2-7H showed higher levels of luciferase 
activity than at 1 µM.  Compound 3-7A (GentianViolet) was the most active at this 
concentration.  At 10 uM concentration (lower panel) all compounds tested except 5-9E 
showed statistically significant increases above the DMSO control, with 3-7A and 7-4H 
being the most active at this concentration.  However only compound 7-4H showed 
higher luciferase activity than at the 5 µM level.  The decreased luciferase activities for 
the other compounds could be due to a general cell cytotoxicity at high concentrations. 
 
 
RT-PCR  
 RT-PCR was performed to verify that the alternative splicing of tau exon 10 
actually occurred in the cells that displayed the increased luciferase activity in Table 1.  
The extraction of total cellular RNA proved to be a difficult task from the cell cultures 
showing high levels of cell death.  The quality of RNA was diminished to the point where 
it was unusable.  Four attempts were performed with those samples, none of which 
worked.  Eventually the medium problem was solved, producing viable cells and good 
RNA, but the gel conditions used did not fully resolve the two alternative splicing 
amplicons (included and excluded exon-10) resulting in improper band separation.  So a 
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previous RT-PCR result obtained by the Zhou lab (Figure 8) was used which shows a 
predominant lower band (denoting exon-10 exclusion) for cells treated separately with 
each of the five compounds (lanes 1-5).  More of the mRNA from the cells treated with 
these five compounds excluded exon 10 rather than included it, as seen in the more 
intense lower band labeled –E10 in Figure 8.  RT-PCR from control cells treated with 
DMSO vehicle (lane 6) shows a slightly upper band intensity denoting the inclusion of 
exon 10.  
Figure 8:  RT-PCR of Tau Exon 10 Region.  mRNA from cells treated separately with each of the five 
compounds was subjected to RT-PCR for tau exon-10, then electrophoresed.  Lanes are as follows: 
Colchicine, Podophyllotoxin, Gentian Violet, Peruvoside, Sanguinarine Nitrate, and DMSO control 
respectively. Note the stronger band in the lower position corresponding to mRNA without exon-10 in 
lanes 1-5, with the exception of the DMSO control (lane 6). 
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DISCUSSION 
 
 The main conclusion of this project was that all five compounds tested were able 
to statistically significantly increase luciferase levels above DMSO vehicle control at 5 
µM concentrations, validating the initial unpublished compound screen done by Zhou’s 
lab. The highest levels of luciferase activity were obtained for compounds 7-4H and 3-7A 
at the maximal concentrations tested here.  The increased luciferase activities for all five 
samples were accompanied by a preponderance of tau mRNA without exon-10 as verfied 
by RT-PCR.  This data shows that such compounds can increase the exclusion of tau 
exon 10, which presumably would lead to a decrease in the production of the larger more 
toxic tau protein in neuronal cells.   
 As explained in methodology, time courses used during the luciferase assay 
experiment included 24 and 48 hours.  After 48 hours no luciferase activity was observed 
(data not shown).  This could be due to the fact that the time period was too long and 
toxic to the cells, especially in the presence of DMSO vehicle, resulting in death.  
Similarly, it was observed that at high concentrations of the compounds the cells died, 
suggesting that the concentration was too toxic for the cells.  It may have been more 
beneficial to try a lower concentration for a longer period of time because a lower 
concentration of a toxic drug will be necessary for human trials. 
 An RT-PCR experiment previously conducted in the Zhou lab was shown in this 
MQP due to the author’s failed RT-PCR attempt.  The author’s RT-PCR attempt was not 
electrophoresed long enough, and no band separation occured.  In addition, the exposure 
time of this gel was also too long, resulting in extremely dark, unresolved bands.   
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However, the RT-PCR result used in this MQP showed that the five samples that showed 
an increase in luciferase activity also showed greater amounts of tau exon-10 exclusion, 
further validating the luciferase assay developed by Yu et al., 2004.  
 Compound 3-7A (Gentian Violet) is known to be a toxic chemical, it is important 
to test other chemicals with similar structures to see if they could be as effective but with 
less cellular toxicity.  Currently, Jianhua Zhou’s lab at the University of Massachusetts 
Medical School is performing High Throughput Screening (HTS) of about 20,000 
chemicals to see if more hits can be discovered.  The hope of HTS is that a certain family 
of drugs will be found to minimize the exclusion of exon 10, which would increase our 
understanding of the tau splicing mechanism, and lead to the design of less toxic 
pharmaceuticals for treatment of tauopathies. 
 In summary, in this project all five compounds tested proved to significantly 
increase the exclusion of tau exon 10 at the 5 µM concentration level.  This MQP 
achieved its overall goal of validating the compounds originally identified by Zhou’s lab 
as facilitating the exclusion of tau exon-10.  In the future, similar compounds may be 
beneficial in the treatment of tauopathies. 
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